Alan D. Dosik, Morton Coleman, Lale Kostakoglu, Richard R. Furman, Jennifer M. Fiore, Daniel Muss, Ruben Niesvizky, Tsiporah Shore, Michael W. Schuster, Patricia Stewart, Shankar Vallabhajosula, Stanley J. Goldsmith and John P. Leonard Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma Cancer 106
Version of Record online: 16 DEC 2005 | DOI: 10.1002/cncr.21606
Iodine I-131 tositumomab was an effective therapy for patients with non-Hodgkin lymphoma. After this radioimmunotherapeutic regimen, patients with progressive disease generally had sufficient hematologic reserve to receive subsequent antilymphoma treatment.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field